var data={"title":"Famotidine, calcium carbonate, and magnesium hydroxide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Famotidine, calcium carbonate, and magnesium hydroxide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6180?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=famotidine-calcium-carbonate-and-magnesium-hydroxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Famotidine, calcium carbonate, and magnesium hydroxide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170010\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dual Action Complete [OTC];</li>\n      <li>Pepcid Complete [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170011\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pepcid Complete [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170022\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antacid;</li>\n      <li>\n        Histamine H<sub>2</sub> Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170014\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Each tablet contains famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heartburn:</b> Oral: One tablet to relieve symptoms; maximum: 2 tablets in 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170018\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Children &ge;12 years and adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170015\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22807020\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22807021\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170002\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, chewable, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dual Action Complete: Famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165 mg [contains calcium 320 mg/tablet, magnesium 70 mg/tablet, phenylalanine 2.2 mg/tablet; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pepcid Complete: Famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165 mg [contains calcium 320 mg/tablet, magnesium 70 mg/tablet; berry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pepcid Complete: Famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165 mg [contains calcium 320 mg/tablet, magnesium 70 mg/tablet; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pepcid Complete: Famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165 mg [contains calcium 320 mg/tablet, magnesium 70 mg/tablet, tartrazine; tropical fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Famotidine 10 mg, calcium carbonate 800 mg, and magnesium hydroxide 165</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169991\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22807022\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets should <b>NOT</b> be swallowed whole; <b>must be chewed completely</b> prior to swallowing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170003\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Heartburn:</b> Relief of heartburn due to acid indigestion and sour stomach</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169997\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170006\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>OTC labeling:</b> When used for self-medication, do not use if you are allergic to famotidine or other acid reducers; trouble or pain swallowing food; vomiting with blood; bloody or black stools; concomitant use with other acid reducers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169995\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tartrazine: Some products may contain tartrazine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC use): When used for self-medication, patients should be instructed to consult their healthcare prescriber prior to using if they have had heartburn &gt;3 months; heartburn with dizziness; heartburn or chest pain with lightheadedness or sweating; chest pain or shoulder pain with shortness of breath; frequent chest pain; chest or shoulder pain spreading to arms, neck, or shoulders; frequent wheezing associated with heartburn; unexplained weight loss; nausea or vomiting; or stomach pain. In addition, patients should contact their health care prescriber if this product is needed for &gt;14 days or if the condition continues or worsens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299313\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169998\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8937&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib.  Management: Separate administration of acalabrutinib from the administration of any antacids by at least 2 hours in order to minimize the potential for a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfacalcidol: May increase the serum concentration of Magnesium Salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: Antacids may decrease the absorption of Allopurinol. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Antacids may decrease the excretion of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Antacids may decrease the absorption of Atazanavir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Antacids may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered while fasting at least 2 hours before antacids. Giving with or 2 hours after antacids is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a caclium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate.  Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Pamidronate; Zoledronic Acid.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Antacids may decrease the absorption of Bromperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Captopril: Antacids may decrease the serum concentration of Captopril. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Antacids may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: Antacids may decrease the absorption of Diacerein. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any calcium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any magnesium-containing product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estramustine: Calcium Salts may decrease the absorption of Estramustine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosinopril: Antacids may decrease the serum concentration of Fosinopril.  Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural magnesium sulfate may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after oral magnesium salts administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural magnesium sulfate is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Antacids may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of an antacid, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine.  Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Antacids may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir.  Management: Separate the administration of ledipasvir and antacids by 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methenamine: Antacids may diminish the therapeutic effect of Methenamine. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiSOPROStol: Antacids may enhance the adverse/toxic effect of MiSOPROStol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption.  Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate administration.  Separating administer of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Sodium Glycerophosphate Pentahydrate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate.  Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Antacids may decrease the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Antacids may decrease the absorption of Quinolones. Of concern only with oral administration of quinolones.  Management: Avoid concurrent administration of quinolones and antacids to minimize the impact of this interaction. Recommendations for optimal dose separation vary by specific quinolone.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. <b> Exceptions: </b>LevoFLOXacin (Oral Inhalation); Moxifloxacin (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones.  Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts.<b> Exceptions: </b>LevoFLOXacin (Oral Inhalation).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir.  Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Antacids may decrease the serum concentration of Riociguat.  Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sotalol: Antacids may decrease the serum concentration of Sotalol.  Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: Antacids may decrease the serum concentration of Sulpiride.  Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Antacids may decrease the absorption of Tetracyclines.  Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trientine: May decrease the serum concentration of Magnesium Salts. Magnesium Salts may decrease the serum concentration of Trientine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir.  Management: Separate administration of velpatasvir and antacids by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287008\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287010\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9886553\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169994\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170005\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323145\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Tums Dual Action Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-800-165 mg (25): $8.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>The pricing data provided represent a median AWP and/or AAWP price for the brand and/or generic product, respectively. The pricing data should be used for benchmarking purposes only, and as such should not be used to set or adjudicate any prices for charging or reimbursement functions. Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F170008\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fulzimed (PH);</li>\n      <li>Kalmax Compositum (EC, PE);</li>\n      <li>Kremil-S Advance (PH);</li>\n      <li>Magard FA (ID);</li>\n      <li>Magstop (ID);</li>\n      <li>Megalex Antiacido (AR);</li>\n      <li>Pepcid Duo (SE);</li>\n      <li>Pepciddual (DE, IT);</li>\n      <li>Pepcidduo (FI, FR, NO);</li>\n      <li>Promag Double Action (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 8937 Version 132.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F170010\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F170011\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F170022\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F170014\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F170018\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F170015\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22807020\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22807021\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F170002\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F169991\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F22807022\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F170003\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169997\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F170006\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169995\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299313\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169998\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14287008\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F14287010\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9886553\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169994\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F170005\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323145\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F170008\" class=\"outlineLink\">Brand Names: International</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8937|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=famotidine-calcium-carbonate-and-magnesium-hydroxide-patient-drug-information\" class=\"drug drug_patient\">Famotidine, calcium carbonate, and magnesium hydroxide: Patient drug information</a></li></ul></div></div>","javascript":null}